Get the Stockscreener App
6.44
0.23%
-0.02
After Hours:
6.44
Capsovision Inc stock is traded at $6.44, with a volume of 69,662.
It is down -0.23% in the last 24 hours and up +16.76% over the past month.
CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. The company's core technology platform is an orally ingestible capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. CapsoVision's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D, directed at the large intestines. Geographically, the company generates the majority of its revenue from the United States.
See More
Previous Close:
$6.46
Open:
$6.46
24h Volume:
69,662
Relative Volume:
0.18
Market Cap:
$320.96M
Revenue:
$13.55M
Net Income/Loss:
$-25.32M
P/E Ratio:
-11.88
EPS:
-0.542
Net Cash Flow:
-
1W Performance:
+2.87%
1M Performance:
+16.76%
6M Performance:
+37.42%
1Y Performance:
+0.00%
1-Day Range:
$6.3129
$6.60
1-Week Range:
$6.00
$6.68
52-Week Range:
$3.4341
$15.37
Capsovision Inc Stock (CV) Company Profile
Name
Capsovision Inc
Sector
Industry
Phone
(408) 370-4790
Address
18805 COX AVENUE SUITE 250, SARATOGA
Compare CV vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CV
Capsovision Inc
|
6.44 | 311.49M | 13.55M | -25.32M | 0 | -0.542 |
ABT
Abbott Laboratories
|
101.05 | 174.29B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
345.86 | 129.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
88.12 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
63.82 | 91.83B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 44.90B | 6.07B | 1.06B | 1.34B | 1.8063 |
Capsovision Inc Stock (CV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Initiated | Roth Capital | Buy |
| Jul-28-25 | Initiated | The Benchmark Company | Speculative Buy |
Capsovision Inc Stock (CV) Latest News
CapsoVision targets 510(k) submission for Gen 2 colon capsule and AI module in Q3 2026 as commercial adoption accelerates - MSN
CapsoVision Inc PE Ratio (TTM) & PE Ratio (TTM) ChartsCV - GuruFocus
CapsoVision (CV) Schedule 13G/A: CID group, Altenza and individuals report ≤5% holdings - Stock Titan
Earnings Preview: CapsoVision to Report Financial Results Post-market on March 26 - Moomoo
Major CapsoVision (CV) holder Shen Ching Hang reports large direct and indirect stake - Stock Titan
Short Interest in CapsoVision, Inc. (NASDAQ:CV) Grows By 35.2% - MarketBeat
Benchmark cuts CapsoVision stock price target to $10 on delayed timeline By Investing.com - Investing.com Australia
Benchmark cuts CapsoVision stock price target to $10 on delayed timeline - Investing.com Australia
CapsoVision (NASDAQ:CV) Price Target Lowered to $10.00 at Benchmark - MarketBeat
CapsoVision 2025 Financial Performance Review - AlphaStreet
CapsoVision revenue up 13% to USD 3.9M in Q4 2025 - Medical Buyer
CapsoVision’s CapsoCam: 360° Panoramic AI-Powered Capsule Endoscopy Solution Expanding Global GI Diagnostics Market 2324323344 - Minichart
Large CapsoVision (CV) holder discloses direct and trust share stakes - Stock Titan
CapsoVision Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: CapsoVision Q4 2025 sees revenue growth, stock dips - Investing.com Australia
CapsoVision Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: CapsoVision Q4 2025 sees revenue growth, stock dips By Investing.com - Investing.com South Africa
CapsoVision Inc reports results for the quarter ended September 30Earnings Summary - TradingView
CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
CV: AI-powered capsule endoscopy drives growth and innovation in noninvasive GI screening - TradingView
CapsoVision 10-K: Revenue $13.6M, EPS $(1.03) — Annual Results - TradingView
CapsoVision (NASDAQ: CV) flags going concern while advancing AI colon capsule - Stock Titan
CapsoVision, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
CapsoVision Faces Deadline to Turn Capital Into Profit Before Runway Collapses - Bitget
CapsoVision (NASDAQ: CV) grows 2025 revenue 15% as net loss widens - Stock Titan
CapsoVision, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
CapsoVision Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
CapsoVision Conference: CEO Maps AI-Driven Capsule Endoscopy Roadmap for Colon and Pancreas Screening - MarketBeat
CapsoVision price target raised to $11 from $7 at Roth Capital - tipranks.com
CapsoVision (CV) director receives 4,045 RSU equity award - Stock Titan
CapsoVision (CV) awards 4,045 RSUs to board director - Stock Titan
CapsoVision (CV) director receives 4,045 RSU grant as board compensation - Stock Titan
CapsoVision (CV) director receives 4,045 RSUs vesting through 2026 - Stock Titan
CapsoVision (CV) awards 4,045 restricted stock units to director - stocktitan.net
[Form 4] CapsoVision, Inc Insider Trading Activity - Stock Titan
CV: AI-powered capsule endoscopy targets multi-cancer detection with global expansion and strong funding - TradingView
CV: CapsoVision advances AI-powered capsule endoscopy with strong pipeline and global expansion - TradingView
CapsoVision’s Strategic Moves Spike Stock as Market Anticipates Growth - timothysykes.com
CapsoVision Surges 13% on Closing $14M Private Placement - StocksToTrade
CapsoVision Closes $14 Million Private Placement and Reports Preliminary 2025 Financial Results - Minichart
CapsoVision closes $14 million private placement financing By Investing.com - Investing.com Australia
CapsoVision, Inc.: Fundamental Analysis and Financial Ratings | H6U | US1409351079 - marketscreener.com
CapsoVision Raises Capital and Refocuses Colon Capsule Strategy - TipRanks
CapsoVision closes $14 million private placement financing - Investing.com
CapsoVision Raises ~$14 Million in Private Placement, Selling 2.87M Shares at $4.883 - tradingview.com
CapsoVision (NASDAQ: CV) secures $14M and pivots colon capsule strategy - stocktitan.net
CapsoVision Announces $14 Million Private Placement Financing - GlobeNewswire
CapsoVision, Inc.: Fundamental Analysis and Financial Ratings | CV | US1409351079 - marketscreener.com
What Is CapsoVision's Roadmap For Growth And Innovation In 2026? - RTTNews
Capsovision Inc Stock (CV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):